ischemia reperfusion injury myocardial infarction
Conditions
Interventions
in a cross-over design all volunteers receive 3 day treatment with atorvastatin
80mg daily or placebo. Between the active treatment period and the placebo
period, a wash-out period of at least 4 wee
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Male -Age 18-50 years -Informed consent -Physical able to perform ischemic exercise
Exclusion criteria
Exclusion criteria: -History of any cardiovascular disease -Hypertension (in supine position: systole > 140 mmHg, diastole > 90 mmHg) -Diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L) -Hyperlipidaemia (random total cholesterol > 6 mmol/l) -Alanine-Amino-Transferase (ALAT) >90 U/L (more than twice the upper level of the normal range) -Creatinine Kinase (CK) >340 U/L (more than twice the upper level of the normal range) -Drug abuse -Concomitant chronic use of medication -Administration of radioactivity in research setting during the last 5 years -Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annexin A 5 targeting in the non dominant thenar muscle after ischemic exercise, as a indicator for ischemia reperfusion injury | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting lipid profile before and after three day therapy with atorvastatin 80mg. Workload performed during ischemic exercise. | — |
Countries
Netherlands
Outcome results
None listed